Login / Register The Most Trusted Name in Medical Education

Nursing

Elsevier's Office of CME offers a variety of courses for the nursing community.

Newborn image 1

Mosby's Essential Nursing CE: Newborn Series

Format: eLearning Activity

Mosby's Essential Nursing CE Newborn Series, sponsored by an educational grant from Mead Johnson Nutrition, is authored and peer reviewed by nurse experts. The four web-based, interactive, multimedia lessons are designed for perinatal nurses, and include a printable Lesson Notebook that is a detailed lesson outline for personal note taking. Elsevier provides the continuing education contact hours.* 

  1. Care of the Stable Newborn -  0.62 contact hours
  2. Newborn and Infant Nutrition -   0.71 contact hours
  3. Newborn Physiology -  0.54 contact hours
  4. Physical Assessment of the Newborn -  0.81 contact hours
*Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing. The provider number is #50-4681. Elsevier is provider approved by the California Board of Registered Nursing. The provider number is CEP 3257.

Click here to register and start earning free contact hours.

 

910701 116 x 144

Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care

Format: Webcast Series

This CME-accredited CME Snapshot™ educational series, Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care is intended for primary care clinicians and other health care providers involved in the ongoing management of patients with chronic obstructive pulmonary disease (COPD). Within each focused activity, an expert pulmonologist and a primary care educator discuss best practices for a specific aspect of managing patients with COPD, including monitoring the disease course over time, maximizing patient function, and individualizing treatment regimens. One activity also addresses patients’ perspectives by incorporating patient-clinician interactions and insights into disease burdens, challenges to good long-term outcomes, and shared decision-making. 

Take Course »

 

Credits: Up to 1.00 AMA PRA Category 1 Credit(s)™
910726 116 x 140

Aerosolized Agents for Airway Clearance in Cystic Fibrosis: When, How, Why? A Roundtable Discussion

Format: Webcast

This activity is presented as a roundtable discussion between three international expert faculty in cystic fibrosis (CF). This expert faculty will discuss the role of aerosolized agents for improving airway clearance, including caveats from their own extensive clinical experience in managing patients with this condition. The faculty will also deliberate on strategies to improve patient adherence to CF therapy in a case study based format. These discussions will support participants in clinical decision making as well as in helping their patients achieve optimal benefit through adherence to their CF therapy.

 

Take Course »

 

Credits: 1.50 AMA PRA Category 1 Credit(s)™
Elsevier EHA 2017 Web 116x140 v3

EMERGING TARGETED THERAPIES IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Format: Medical Meeting Reporter

This webcast on relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is based on a roundtable discussion by three experts, who provide an overview of challenges in the treatment of R/R ALL and summarize and discuss the latest data presented during the European Hematology Association (EHA) Annual Congress 2017, held on June 22–25 in Madrid, Spain. Progressing clinical trial outcomes of targeted therapies for R/R ALL, such as the anti-CD22 immunoconjugate inotuzumab ozogamicin, the anti-CD19 bi-specific T-cell engager (BiTE) blinatumomab, and CAR-T cell therapy will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with R/R ALL.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910687 116x140

Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary Care

Format: Webcast

This CME-accredited Through Your Patient’s EyesTM program is intended for primary care providers and other clinicians who manage patients with asthma. This educational activity has been designed to highlight issues faced by people living with asthma, including patients’ perspectives on the burdens of severe disease, difficulties related to suboptimal health literacy, and potential hurdles that can arise in busy healthcare practices. Specialist and primary care faculty discuss practical advice on overcoming these challenges, how to best coordinate multidisciplinary care, and actionable recommendations on identifying, comprehensively assessing, and longitudinally managing patients with severe asthma. As a result, clinician learners will be better prepared to engage and educate their patients with severe asthma, while improving long-term outcomes through personalized evidence-based care.  

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™ or 1.00 Nursing Contact Hours
910734 116 x 140

CYSTIC FIBROSIS INTERVIEW WEBCAST SERIES

Format: Webcast

This activity includes eight 30-minute modules that bring learners up to date on all aspects of cystic fibrosis (CF) treatment and management. Dr. John P. Clancy interviews eight experts in the CF field, each with their own specialization. The individual modules will focus on different areas of CF care, ranging from newborn screening to long-term real world efficacy and safety data. Each module is worth approximately 0.5 CME/CNE credits.

 

Take Course »

 

Credits: 8 Modules Total - Approx. 0.5 AMA PRA Category 1 Credit™ / CNE Credits Each
910655 116 x 140

Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis

Format: Webcast

The content for this activity is based on the satellite symposium, “Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis”, that was presented at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida on October 28, 2016. The content highlights the latest advancements, particularly in CFTR-based therapeutics, for the treatment of patients with cystic fibrosis. Expert faculty discuss the most up-to-date analysis for clinical decision-making, including updates on assessment, monitoring, and management of patients treated with CFTR modulator therapies. The goal of this activity is to increase the knowledge and competencies of the multidisciplinary team involved in the management of patients with CF, and provide strategies for improving the lives of patients. Upon completion of this activity, healthcare providers will be better equipped with imperative information for creating more effective personalized treatment plans and improving patient outcomes.

Register »

Credits: 2.00 AMA PRA Category 1 Credit(s)™
thumbnail

Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability

Format: Webcast

Effective treatment of major depressive disorder with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and, often, intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. The latest data on multimodal therapies indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and neurotransmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.

Register»

Credits: 3.0 AMA PRA Category 1 Credits™
910561 125 x 125

REMS Update 2017: Risk Evaluation and Mitigation Strategy

Format: Webcast

This educational supplement has been created to educate healthcare professionals on the safe and proper use of Extended-Release (ER) and Long-Acting (LA) opioids for chronic pain management. Opioids are the cornerstone of modern pain management. They are highly complex molecules which require knowledge and integration of basic science, clinical, pharmacological, psychosocial, abuse, diversion, and public health aspects of opioids. This Opioid Risk Evaluation and Mitigation Strategy (REMS) supplement is a valuable tool that can be utilized daily by everyone in your practice. Continuing Medical Education (CME/CE) credits are available for studying this supplement and completing the online test. The supplement and test can be completed in a little more than three hours, but it will have a lifetime benefit!

Take Course »

Credits: 3.00 AMA PRA Category 1 Credit(s)™ or 3.0 Nursing Contact Hours
910666 116 x 140

Where Are We Now? A Clinicians’ Guide to the Use of Follow-on Insulin for Patients with Diabetes

Format: Webcast

Insulin has been used as a standard treatment for patients with diabetes for almost 100 years.  Over time, advances in insulin development have improved its pharmacologic properties.  Most recently, the US Food and Drug Administration approved a novel, follow-on basal insulin agent, with more expected to be commercially available in the near future. With the imminent availability of follow-on basal insulin agents, clinicians need to be aware of the potential benefits and concerns in order to facilitate informed decision making and to provide the best possible advice and guidance to their patients with diabetes.  This program will review how follow-on insulin products are developed, manufactured, and receive regulatory approval; evaluate clinical trial data for new and emerging follow-on basal insulin agents; and provide practical information and guidance on how they may be incorporated into clinical practice.  While it is unknown how follow-on basal insulins will affect patient outcomes, they have the potential to increase access to treatment among patients with diabetes and reduce healthcare costs.

Take Course »

Credits: 1.25 AMA PRA Category 1 Credit(s)™ or 1.25 Nursing Contact Hours